11 Best Extremely Profitable Stocks to Buy According to Analysts

3. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

TTM Net Profit Margin: 31.07%

Number of Hedge Fund Holders: 68

Analyst Upside Potential: 49.59%

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company focused on inventing, developing, manufacturing, and commercializing medicines for serious diseases. The company utilizes proprietary technologies like VelociSuite, to produce optimized human antibodies and bispecific antibodies. Its marketed products include EYLEA, Dupixent, Libtayo, Kevzara, and others.

On March 14, Evan Seigerman, an analyst from BMO Capital, maintained a Buy rating on the stock with a price target of $903. Seigerman views the recent court decision regarding the Eylea biosimilar case as a modest setback but believes it does not overshadow Regeneron’s long-term growth potential. He is particularly optimistic about Regeneron Pharmaceuticals, Inc.’s (NASDAQ:REGN) robust pipeline, especially in oncology and other therapeutic areas. Moreover, he also believes that the upcoming data releases for products like itepekimab in COPD and fianlimab in NSCLC/melanoma are expected to drive growth. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best extremely profitable stocks to buy according to analysts.

Amalthea Fund stated the following regarding Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in its Q3 2024 investor letter:

“Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – the biggest loser in the book by absolute dollars. Regeneron is a large position for us. We wrote the position up in June 2021 letter. The stock has almost doubled since the original write-up, but it is down on the month. Allow some time for an explanation There are two ways of looking at Regeneron. The sum-of-the-parts way and the platform way.

Regeneron has 11 approved drugs but two comprise most of the cash flows. The two are Eylea and Dupixent.

Eylea is a VEGF drug that is injected into patients’ eyes and stops macular degeneration (the main cause of blindness in old people). The drug stops capillaries growing in the retina…” (Click here to read the full text)